Skip to main content

Animations

MJFF Publications

4801 - 4810 of 6509 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2021
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41531-022-00297-9
    Citation Count: 42
  • Summary Details
    OPEN
    Title: Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.2112712119
    Citation Count: 53
  • Summary Details
    OPEN
    Title: NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation
    Journal Name: International Journal of Inflammation
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1155/2022/2337363
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Fine-mapping of Parkinson’s disease susceptibility loci identifies putative causal variants
    Journal Name: Human Molecular Genetics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/hmg/ddab294
    Citation Count: 42
  • Summary Details
    OPEN
    Title: Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients
    Journal Name: Metabolites
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3390/metabo12020149
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1186/s13024-022-00520-4
    Citation Count: 20
  • Summary Details
    OPEN
    Title: LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains
    Journal Name: PLOS Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1371/journal.pbio.3001427
    Citation Count: 25
  • Summary Details
    OPEN
    Title: The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity
    Journal Name: Journal of Cell Biology
    Publisher: Rockefeller University Press
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1083/jcb.202010065
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.2121609119
    Citation Count: 49
  • Summary Details
    OPEN
    Title: SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic
    Journal Name: Journal of Cell Biology
    Publisher: Rockefeller University Press
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1083/jcb.202111018
    Citation Count: 37
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.